Results: Among the 187 patients with severe AS, 139 (74.3%) underwent medical management while 48 (25.7%) underwent BAV. Patients undergoing BAV were older (81.7 vs 85.8 years, p=0.01) and more likely to be female (33.3% vs 18.6%, p=0.02). No differences in individual covariates of the STS-PROM score or functional characteristics including living/mobility status or cognitive impairment were noted. 77(41.6%) deaths occurred over the study period. Patients treated with BAV had a significantly lower chance of death compared to those managed medically (HR 0.46, 95% CI 0.25-0.86, figure), even after adjustment for significant univariate clinical and functional predictors. Conclusion: In severe AS, BAV was independently associated with lower mortality when compared to medical therapy despite being performed in older patients. Due to limitations in access to TAVI, studies are warranted to assess whether BAV as opposed to medical therapy, can reduce wait-list mortality.